What’s New with Innocoll?
Catch up on the latest developments.
Giovanni Escobar assumes the role of Chief Operating Officer at Innocoll
Innocoll Holdings Ltd. Appoints Kimball Hall as Chief Executive Officer
Innocoll and DURECT Announce U.S. launch of POSIMIR®
Innocoll Announces Strategic Investment from Hillhouse Investment
Innocoll Announces Publication of Positive Results from Pivotal Clinical Trial of POSIMIR in Arthroscopic Subacromial Decompression
Innocoll Announces Positive Topline Results for XARACOLL® (bupivacaine hydrochloride) Implant in a Phase 3 Study to Support Expanded Use
Innocoll Announces Co-Promotion Agreement for Hernia Product Portfolio
Innocoll Announces Successful Completion of Debt Refinancing
DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution)
Innocoll Biotherapeutics plc Announces First Patients In Phase 3 Clinical Trials for Label Expansion of Xaracoll® (bupivacaine hydrochloride) Implant